Graft survival benefit to be expected of new immunosuppresssive regimens

Transplantation Reviews

Volumn 17, Issue 4, 2003, Pages 187-193

  Ekberg, Henrik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MORTALITY; NEPHROTOXICITY; OUTCOMES RESEARCH; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0345099476     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2003.08.004     Document Type: Article

References (22)

1. Murray JE, Merrill JP, Harrison JH, et al: Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963, 268:1315
2. European Multicentre Trial Group: Cyclosporin in cadaveric renal transplantation: One-year follow up of a multi-centre trial. Lancet 1983, 2:986
3. Halloran P, Mathew T, Tomlanovich S, et al: Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997, 63:39
4. European Mycophenolate Mofetil Study Group: Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999, 68:391
5. European Mycophenoalte Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and steroids for prevention of acute rejection. Lancet 1995, 345:1321
6. Ojo AO, Meier-Kriesche HU, Hanson JA, et al: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2001, 69:2405
7. Meier-Kriesche H-U, Ojo AO, Leichtman AB, et al: Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000, 11:2366
8. Ekberg H, Bäckman L, Tufveson G, et al: Daclizumab prevents acute rejection and improves patient survival posttransplantation: One year pooled analysis. Transplant Int 2000, 13:151
9. Mayer AD, Dmitrewski J, Squifflet JP, et al: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997, 64:436
10. Nashan B, Moore R, Amlot P, et al: CHIB 201 International Study Group. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997, 350:1193
11. Flechner SM, Goldfarb D, Modlin C, et al: Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002, 74:1070
12. Hariharan S, McBride MA, Cherikh WS, et al: Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002, 62:311
13. Meier-Kriesche H-U, Baliga R, Kaplan B: Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003, 73:1291
14. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual frame-work. Clin Pharmacol Ther 2001, 69:89
15. Vianello A, Mastrosimone S, Calconi G, et al: Influence of donor age on cadaver kidney graft function and survival: Univariate and multivariate analyses. Nephron 1993, 65:541
16. Rao KV, Kasiske BL, Odlund MD, et al: Influence of cadaver donor age on posttransplant renal function and graft outcome. Transplantation 1990, 49:91
17. Rosengard BR, Feng S, Alfrey EJ, et al: Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2002, 2:701
18. Kasiske BL, Andany MA, Danielson B: A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis 2002, 39:762
19. Paraskevas S, Kandaswamy R, Humar A, et al: Predicting long-term kidney graft survival: Can new trials be performed? Transplantation 2003, 75:1256
20. Meier-Kriesche H-U, Schold J, Kaplan B: Is renal function predictive of graft survival? Good correlation but poor prediction [abstract]. Am J Transplant 2003, 3(Suppl):314
21. Siddiqi NA, Cherikh WS, Cheng Y, et al: Composite endpoint (CEP): A tool to evaluate transplant survival - An analysis of UNOS/OPTN data [abstract]. Am J Transplant 2003, 3(Suppl):449
22. Bumgardner GL, Hardie I, Johnson RW, et al: Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001, 72:839